Laid off from AstraZeneca.

AstraZeneca has kept its US headquarters in Wilmington, Delaware, through years of cuts and a 2013 decision to move research to Maryland, as its Delaware workforce shrank. Its latest round came under a 2026 savings program its finance chief said would bring job losses but no net reduction in jobs.

What we know about AstraZeneca severance and layoffs

  • 626 employees on AstraZeneca's Delaware WARN notice dated November 12, 2026
  • Up to $2.0 billion in one-time restructuring costs for the 2026 savings program
  • 1,150 US sales jobs in the December 2011 cut, roughly 24% of sales staff
  • 1,200 Wilmington jobs in AstraZeneca's 2013 plan to cut or move work by 2015
  • About 1,500 Delaware employees after the 2016 cuts, from about 4,000 in 2010
  • 700 US commercial positions in AstraZeneca's December 2016 cuts, about 120 in Wilmington

The most recent AstraZeneca layoff we've found

AstraZeneca's WARN notice to Delaware, dated November 12, 2026, counts 626 employees affected, and the state's WARN register gives the company's Wilmington address without saying which jobs the notice covers. Roughly 600 commercial jobs in AstraZeneca's US respiratory and immunology business had been cut, an early move under its three-year cost-saving program, according to a Bloomberg report that Stocktwits relayed on November 13.

What AstraZeneca layoffs have meant for employees

Part of what Delaware lost was work that moved rather than ended. In 2010 AstraZeneca's spokesman, Tony Jewell, said the company planned no cutback in its later-stage development work in Delaware, according to a 2010 Inquirer report, but in 2013 it said its research and development functions would go mainly to Gaithersburg, Maryland, where it had inherited a research facility when it bought MedImmune, and that about 170 more jobs would move to other company sites. Sen. Tom Carper told the Wilmington News Journal that the company had considered closing its Delaware operations, and a spokesman said it decided to keep Wilmington as its North American commercial headquarters, the 2013 Inquirer story reported.

A transfer hasn't always kept a job safe. In September 2016 AstraZeneca filed a Pennsylvania notice covering 134 people as it closed its Fort Washington office and said those jobs would move to Wilmington as of October 3, and some of the workers who transferred were among those cut that December, the 2016 Inquirer story reported. If AstraZeneca proposes a transfer, you can tally the moving costs and keep an outside search going after you relocate, since the cuts that included some Fort Washington transfers were announced about two months after those jobs shifted to Wilmington.

AstraZeneca's executives have presented the 2026 program as a shift in where its people work. "There'll be job losses," chief financial officer Aradhana Sarin told a media call, though she said "it won't lead to a net reduction in jobs," AFP reported, and chief executive Pascal Soriot told journalists "you don't spend $1.5 billion without creating jobs." Executives said some departments faced cutbacks or restructuring while others would re-skill and hire for emerging needs, according to Reuters, and the company's third-quarter filing said it had opened a research center in Kendall Square, Cambridge, Massachusetts, built to hold nearly 2,000 researchers and scientists. Anyone cut in 2026 can track AstraZeneca's postings for the departments executives said would re-skill and hire.

AstraZeneca has tied research cuts to its choices of diseases and drugs. In 2010 it scored its programs on how common each disease was, its prospects of finding useful compounds and whether payers would pay, then ceased discovery efforts for several psychiatric disorders and eliminated the psychiatric-drug laboratory, about a third of its Delaware research staff, the 2010 Inquirer report said, while expecting its Boston research site to grow as employees transferred in. In 2026 Soriot said shifting focus from patent-expiring drugs such as Farxiga and Brilinta to oncology and rare diseases could make some research roles redundant, the Reuters report said.

Contract sales staff have been caught in AstraZeneca's changes too. In 2016 the company stopped contracting sales representatives from Publicis Touchpoint Solutions, a move that reportedly affected 1,600 jobs, BioPharma Dive reported, and in 2026 it scaled back its contract with Syneos Health, which helps sell its products in the US, Bloomberg reported, according to Stocktwits. If you sell AstraZeneca drugs for a contract firm, you can follow that firm's announcements about its AstraZeneca contract.

Anyone whose job was in Wilmington can read about Delaware unemployment benefits, and field staff can find unemployment benefits by state. If separation papers come your way, you can look into negotiating severance, and if your health plan was AstraZeneca's, into how COBRA works. If the cuts Bloomberg tied to the savings program ended your role and a recruiter asks why, AstraZeneca's description of the program, a redeployment of resources toward its drug pipeline, is yours to use when explaining a layoff.

A sourced history of AstraZeneca layoffs

  • November 2026, US respiratory and immunology sales cuts

    AstraZeneca cut about 600 jobs from its US commercial teams in respiratory and immunology, including staff marketing the asthma drugs Breztri and Airsupra, Bloomberg reported, according to Stocktwits. Some of the people affected were expected to be reassigned within the company.

  • October 2026, Reshaping for Sustainable Growth program

    AstraZeneca's third-quarter results launched a three-year program to redeploy resources, putting its one-time restructuring cost at as much as $2.0 billion and expecting $1.5 billion in annualized pre-tax run-rate benefits, with the work essentially finished by the end of 2029.

  • January 2019, Boulder and Longmont plant closings

    AstraZeneca said it would close its two Colorado plants, in Boulder and Longmont, and that the 210 staff on its January 8 state notice would leave March 22, with the sites fully decommissioned by the end of 2019, BioProcess International reported.

  • December 2016, US commercial business cuts

    AstraZeneca said it was eliminating about 700 US commercial positions, roughly 80 of them vacant, to reflect the lower US revenue it expected in 2017. About 120 were Wilmington-based roles and the rest field sales and non-sales jobs across the country, the Philadelphia Inquirer reported.

  • March 2013, Wilmington research move to Maryland announced

    AstraZeneca said it would eliminate about 650 US jobs, most from Wilmington, and move about 300 positions to Gaithersburg, Maryland, and about 170 to other sites by the end of 2015, the Philadelphia Inquirer reported.

  • December 2011, US sales force cut

    AstraZeneca's sales force was to lose about 1,150 representatives and leadership positions, roughly 24% of its US sales organization, with the impact varying by geography and selling team and decisions final by early February 2012, according to a Business Wire release.

  • October 2011, US commercial staff cuts

    AstraZeneca said its US commercial business would lose about 400 jobs, 70 of them already vacant, with sales positions left out of the cuts, BioSpace reported.

  • March 2010, Wilmington psychiatric research group phased out

    AstraZeneca said about 550 Wilmington scientists and support staff would lose their jobs by the end of 2011 as it phased out a research group working on psychiatric drugs, the Philadelphia Inquirer reported.

What to do if you're laid off from AstraZeneca

AstraZeneca layoff and severance questions

What severance has AstraZeneca given laid-off employees?

When it cut US commercial jobs in October 2011, AstraZeneca said employees who chose to leave would get the same severance package as those who were cut, and a spokesman declined to comment on the package itself, BioSpace reported. That December, a company release said sales employees could self-identify to potentially leave as it cut its sales force.

Has AstraZeneca filed WARN notices?

Yes. Delaware's register records one dated November 12, 2026, for 626 affected employees, and lists the company's address as 1800 Concord Pike in Wilmington. In Colorado, a notice dated January 8, 2019 covered the Boulder and Longmont plant closings, BioProcess International reported, and in 2016 the company told Pennsylvania that closing its Fort Washington office would affect 134 people, the Philadelphia Inquirer reported.

Why did AstraZeneca close its Boulder and Longmont plants?

AstraZeneca said it was consolidating its biologics manufacturing in one drug-substance plant in Frederick, Maryland, and because neither Colorado site was licensed for commercial operations, no supply had to move, BioProcess International reported. It had bought the Boulder plant from Amgen in 2015 and the Longmont plant in 2016, and it said both would be kept for a potential sale.

Sources for this page